Highest-materiality recent filing
John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.
Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device
Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.
Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition
Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.
Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition
Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26
Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.
Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing
OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.
OraSure replaces KPMG with Grant Thornton as auditor; discloses material weakness
KPMG dismissed after 2023 audit completion; Grant Thornton appointed for FY2024, effective upon dismissal.
OraSure Q1 record revenue $155M, GAAP EPS $0.37; guides Q2 rev $62-67M
Total net revenue $155.0M (+129% YoY); InteliSwab revenue $118.3M (+33% sequential).
OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce
Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).
Contract from US Defense Logistics Agency for InteliSwab COVID-19 Rapid Test; runs Nov 2022 to Nov 2023.
OraSure posts record Q3 revenue of $116.5M, up 116% YoY; InteliSwab drives growth
GAAP net income $5.3M ($0.07 diluted EPS) vs. loss of $15.0M a year ago; non-GAAP EPS $0.13.
OraSure appoints Ken McGrath as CFO; three directors resign as part of strategic transformation
Ken McGrath named CFO effective Aug 8, 2022; succeeds Scott Gleason, who served as interim CFO since Sep 2021.
OraSure Q2 revenue record $80.2M (+39% YoY) but GAAP EPS ($0.26); InteliSwab sales surge 95% QoQ
GAAP net loss of $18.8M vs. $1.4M loss in Q2 2021; gross margin fell to 34.4% from 53.2%.
OraSure General Counsel and CCO to depart June 25 after citing organizational changes
Agnieszka M. Gallagher, EVP, General Counsel and Chief Compliance Officer, notified termination with Good Reason on June 3, 2022.
OraSure appoints Carrie Eglinton Manner CEO effective June 4; ends strategic alternatives review
Carrie Eglinton Manner appointed President and CEO, effective June 4, 2022; replaces interim CEO Nancy Gagliano.
OraSure Q1 record revenue $67.7M (+16% YoY) but net loss $20M, InteliSwab scales
Net loss of $20.0M ($0.28 diluted EPS) vs net income of $3.8M ($0.05) in Q1 2021; operating loss $16.0M.
On May 8, 2025, Kathleen G. Weber notified OraSure Technologies, Inc. (the “Company”) of her resignation as Chief Product Officer of the Company, effective June 30, 2025.
the Board appointed John P. Kenny as a new member of the Board, with such appointment to be effective as of the Effective Date.
the Board appointed Robert W. McMahon as a new member of the Board, with such appointment to be effective as of the Effective Date.
On March 15, 2023, Scott Gleason, who currently serves as the Company’s Senior Vice President of Corporate Communications and Investor Relations, notified the Company of his resignation from the Company, effective May 26, 2023, in order to pursue another opportunity.
On November 7, 2022, the board of directors of OraSure Technologies, Inc. (the “Company”) appointed Kathleen G. Weber, the Company’s current President of Molecular Solutions, as the Company’s Chief Product Officer, effective November 14, 2022.
Mr. McGrath will succeed Mr. Scott Gleason, who has served as the Company’s Interim Chief Financial Officer since September 2021.
On August 8, 2022, the board of directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) appointed Ken McGrath as the Company’s Chief Financial Officer, effective August 8, 2022 (the “Effective Date”).
Ms. Weber has notified the Company of her decision to rescind her resignation as President of Molecular Solutions.
On June 3, 2022, Agnieszka M. Gallagher, who currently serves as OraSure Technologies, Inc.’s (the “Company”) Executive Vice President, General Counsel and Chief Compliance Officer, notified the Company of her termination of her employment with the Company with Good Reason (as defined in her employment agreement, dated as of November 29, 2021) related to Company organizational changes.
Ms. Eglinton Manner will be appointed by the Board to serve as a Class I director on the Board as of the Effective Date.
the board of directors (the “Board”) of the Company will appoint Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022
Dr. Gagliano will resign, effective June 4, 2022, from her position as the Company’s interim Chief Executive Officer.
Max materiality 0.78 · Median 0.50 · Most common event earnings